Rivaroxaban tops DOACs for GI bleeds

New evidence that rivaroxaban is associated with higher rates of gastrointestinal bleeding than either apixaban or dabigatran may help guide oral anticoagulant selection. A nationwide study from Iceland, comprising 5,868 patients commencing apixaban, dabigatran or rivaroxaban between 2014 and 2019, identified 241 GI bleeding events including 146 major bleeds. All bleeding events identified initially by ...

Already a member?

Login to keep reading.

© 2021 the limbic